POPULARITY
Categories
340 episodes with Abstract
140 episodes with Abstract
91 episodes with Abstract
119 episodes with Abstract
89 episodes with Abstract
61 episodes with Abstract
57 episodes with Abstract
37 episodes with Abstract
24 episodes with Abstract
51 episodes with Abstract
40 episodes with Abstract
27 episodes with Abstract
31 episodes with Abstract
27 episodes with Abstract
13 episodes with Abstract
22 episodes with Abstract
19 episodes with Abstract
18 episodes with Abstract
23 episodes with Abstract
20 episodes with Abstract
33 episodes with Abstract
13 episodes with Abstract
16 episodes with Abstract
44 episodes with Abstract
16 episodes with Abstract
14 episodes with Abstract
16 episodes with Abstract
30 episodes with Abstract
12 episodes with Abstract
12 episodes with Abstract
12 episodes with Abstract
13 episodes with Abstract
25 episodes with Abstract
19 episodes with Abstract
9 episodes with Abstract
10 episodes with Abstract
8 episodes with Abstract
8 episodes with Abstract
6 episodes with Abstract
20 episodes with Abstract
11 episodes with Abstract
7 episodes with Abstract
8 episodes with Abstract
7 episodes with Abstract
6 episodes with Abstract
5 episodes with Abstract
8 episodes with Abstract
15 episodes with Abstract
14 episodes with Abstract
8 episodes with Abstract
7 episodes with Abstract
7 episodes with Abstract
6 episodes with Abstract
6 episodes with Abstract
8 episodes with Abstract
7 episodes with Abstract
5 episodes with Abstract
8 episodes with Abstract
12 episodes with Abstract
12 episodes with Abstract
6 episodes with Abstract
6 episodes with Abstract
7 episodes with Abstract
6 episodes with Abstract
6 episodes with Abstract
4 episodes with Abstract
5 episodes with Abstract
5 episodes with Abstract
7 episodes with Abstract
7 episodes with Abstract
7 episodes with Abstract
5 episodes with Abstract
6 episodes with Abstract
4 episodes with Abstract
5 episodes with Abstract
7 episodes with Abstract
6 episodes with Abstract
2 episodes with Abstract
2 episodes with Abstract
3 episodes with Abstract
4 episodes with Abstract
4 episodes with Abstract
6 episodes with Abstract
4 episodes with Abstract
5 episodes with Abstract
8 episodes with Abstract
4 episodes with Abstract
3 episodes with Abstract
4 episodes with Abstract
86 episodes with Abstract
4 episodes with Abstract
11 episodes with Abstract
6 episodes with Abstract
4 episodes with Abstract
8 episodes with Abstract
4 episodes with Abstract
5 episodes with Abstract
3 episodes with Abstract
4 episodes with Abstract
3 episodes with Abstract
5 episodes with Abstract
3 episodes with Abstract
4 episodes with Abstract
5 episodes with Abstract
5 episodes with Abstract
5 episodes with Abstract
3 episodes with Abstract
74 episodes with Abstract
11 episodes with Abstract
3 episodes with Abstract
6 episodes with Abstract
3 episodes with Abstract
4 episodes with Abstract
70 episodes with Abstract
3 episodes with Abstract
3 episodes with Abstract
3 episodes with Abstract
32m 48s
Jul 28
1h 4m 36s
Apr 19
1h 41m 56s
Oct 3
1h 22m 54s
Apr 14
59m 33s
Sep 27
42m 55s
Apr 11
55m 46s
Aug 1
1h 36m 49s
Jan 1
Jackie Sanders is an abstract artist based in Raleigh, NC. Her work explores the layering and manipulation of organic and geometric forms as a way to transform life's mundane moments into memorable experiences. Jackie is the co-host of the Level Up Artist Podcast and a creative business mentor to career minded artists through her Level Up Artist Membership Community. Jackie Sanders studied at Virginia Tech where she earned her BA in Studio Art, B.F.A in Art History and M.F.A in Material Culture and Public Humanities. She currently has a community facing art studio in downtown Raleigh, NC. J Sanders Studio Contact Info: ● Website: https://www.jaclynsanders.com/bio ● Instagram: @JSandersStudio | https://www.instagram.com/jsandersstudio ● Facebook: https://www.facebook.com/jsandersstudio ● LinkedIn: https://www.linkedin.com/in/sandersjaclyn/ ● Youtube: https://www.youtube.com/channel/UCHEfWvmFXZZ6Z_SW2lMSwCg ● Google Business Profile: https://g.page/r/CTv4hqbD1hgIEB0/review ● TikTok: @JSandersStudio Level Up Artists Podcast: ● Website: https://www.levelupartists.com/ ● Instagram: @LevelUpArtists | https://www.instagram.com/levelupartists/ ● Apple Podcast: https://podcasts.apple.com/us/podcast/level-up-artists/id1565253198 ● Spotify: https://open.spotify.com/show/1kZHh0RwXzYFkeZtvphpTt ● Youtube: https://www.youtube.com/channel/UCRdrDkCoOpNgFHWB1gmpv6A ● Google Podcast: https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy80NDY4NTMxNC9 wb2RjYXN0L3Jzcw?sa=X&ved=0CAYQrrcFahcKEwiwtfbJhLDwAhUAAAAAHQAAAAAQ Ag Thank you for listening to The Curious Creatrix podcast. Your donation helps us continue to spread creativity throughout the land. Thank you! https://www.paypal.com/donate?hosted_button_id=2PM3V82XDS7GA Beautiful music: Good Friends Inc by Jonathan Boyle
GROUPER "DISORDERED MINDS"SUNN O))) & ULVER "LET THERE BE LIGHT"LINGUA IGNOTA "I AM THE BEAST"MYSTIC CHARM "WINDOW OF REALITY"CARCINOGEN "PETRI DISH"WOLF EYES "UNTITLED"GEORGE BRAITH "BRAITH-A-WAY"CATALYST "MAIL ORDER"FLYING LOTUS "ANDROMEDA"FLYING LOTUS "REMIND U"
A conversation with Helen Frankenthaler Foundation Executive Director Elizabeth Smith about a new exhibit of Frankethaler's work currently on display at Gagosian's 24th Street gallery in New York. “Drawing within Nature: Paintings from the 1990s” features more than a dozen works by Frankenthaler made during a period when she took inspiration from the environment near her Connecticut studio on Long Island Sound. The conversation touches on Frankenthaler's life, career and this latest exhibit.https://gagosian.com/exhibitions/2023/helen-frankenthaler-drawing-within-nature-paintings-from-the-1990s/https://www.frankenthalerfoundation.org/
Each type of painting media that an abstract artist uses has specific qualities that make it suitable for certain approaches-- and less so for others. As part of your studio practice, it's important to understand and work with the qualities of different media rather than trying to push against their nature. And it is also exciting to explore outside your typical media to see what each has to offer. Today we'll look at several media used for abstract painting—oil, acrylic, encaustic, watercolor, and mixed media approaches and touch on the benefits and challenges of each. A basic art theory concerns the idea that each art media has unique characteristics to explore and exploit. There is also plenty of middle ground; various media lend themselves to layering, for example. But in exploring various media for different purposes, you may discover new ideas and directions for your work. Water based media tend to offer possibilities for spontaneity, while oil painting offers special luminosity of color. The material qualities of various paints also play a special role in abstraction, when color, line, and physical texture can be important be an important presence for their own sakes. Along with choosing painting media that is in line for your intentions, the tools associated with the medium are a consideration. Experimenting with tools that are outside traditional choices can be exciting, but if you are truly a brush painter, for example, you would probably work best with a fluid media like oil, acrylic, watercolor, and gouache rather than thicker media like oil mixed with cold wax medium, or encaustic. Exploring these different media is exciting, and often leads to a cross-pollination of ideas. For example, you might work through several iterations of an image using water-based media that sets up quickly, and then moving some of those ideas into oil. Or you might increase the scale of a small acrylic study to a large mixed media piece. A shape that you play with in acrylic may take on more depth or dimensionality when you build it up in layers of oil paint. Each medium has distinct effects and potential. Thanks to everyone who has been sharing the show and donating! If you would like to donate to the Messy Studio Podcast donate here (https://www.paypal.com/donate?token=Yyrf7Ht1DYfkYzAaWNoW8zuvCpTryLYsxY2VAj4qGZ3o2o4F7xHGv4VmDDef7kFxuvbgpz_z4jUa-z7F). When you buy art supplies at Blick remember to use our affiliate link to support the podcast! Bookmark this link and then you don't even have to think about it again. This is one of the best ways to support the show. It takes a few seconds and costs you nothing! The Blick website works exactly the same way, but we earn 10% every time you buy art supplies. www.messystudiopodcast.com/blick What's new At Cold Wax Academy? Rebecca and Jerry are wrapping up their winter quarter of online sessions at Cold Wax Academy, where as always members have access to in-depth and varied content for learning, growth, and support. Their Winter quarter included presentations by guest authors Eric Maisel (may-ZEL) and Shaun McNiff, a painting clinic for works in progress, and live sessions on procrastination, tips on photographing your artwork, and source ideas for your paintings. All of these sessions and many more are available as video recordings in the member library. As a member, you can also access the private Facebook page and the community there of informed and supportive artists who post paintings, ask questions and initiate discussions. It's never too late to join Cold Wax Academy! Stay tuned for a list of topics to be covered in the upcoming Spring Quarter and please visit http://www.coldwaxacademy.com for more information as well as basic information about using cold wax medium. Please visit http://www.coldwaxacademy.com for more information. Here is what a member named Sandy has to say about her own experience with Cold Wax Academy: "Rebecca and Jerry have presented the most professional, authentic and structured approach to a creative activity I have ever come across. Their selfless sharing of all their knowledge and encouragement is a gift in my life unsurpassed." Also-- please visit https://www.espacioart.org to learn about Rebecca and Jerry's newest project, Espacio, dedicated to providing beautiful living and working spaces for artists and writers. Espacio's first offering is Casa Clavel, a modern, fully equipped house opening this September in the beautiful cultural city of San Miguel de Allende, Mexico. A few booking openings are still available in 2023, so please incquire if you are interested. Have an art related product, service, or event you would like to advertise on the Messy Studio Podcast? Email Ross at rticknor.core@gmail.com (mailto:rticknor.core@gmail.com) for current mid-roll advertising rates. For more from The Messy Studio: www.messystudiopodcast.com www.facebook.com/messystudiopodcast For more from Rebecca Crowell: www.rebeccacrowell.com www.coldwaxacademy.com The Messy Studio Podcast is a Tick Digital Media Production.
Today's guest, Eleanor Scott Davis is an abstract expressionist painter based in Raleigh, North Carolina. She attended Wake Forest University where she studied English and Studio Art. She went on to earn a Masters of Fine Art in Creative Writing with a concentration in poetry. While the written word remains a passion, Eleanor Scott ultimately chose to forgo the pen for a paintbrush. She is attracted to abstract art because, like poetry, it leaves the door open for individual interpretation. Eleanor Scott considers her artistic process to be directly linked to her role as a mother. Joining her in her bright studio, you will often find one (or all three!) of her daughters. She is frequently pulled away mid-brushstroke by the needs of her children and has come to value these moments of distraction as a tool that strengthens her art, forcing her to step away, evaluate and return with fresh eyes. The result is a deeply-layered, richly-textured, and multidimensional use of color. She considers her work a chronicle of motherhood: a balance of energy, chaos, unpredictability, and pure joy. Eleanor Scott's paintings have been featured in numerous publications and can be found in homes and corporate collections across the United States. We know listeners will love hearing her story! --- Support this podcast: https://anchor.fm/howdshedothat/support
“One year from the day I started, I had a piece at the Louvre as a modern art master,” shares Beth Bowen, international abstract artist. Beth was living a comfortable life until everything changed when her mother passed away in 2013. She realized that life was too short to continue letting fear hold her back from living and ended up filing for divorce. She didn't have a career and was struggling financially, so therapy became too expensive. Not one to give up, Beth decided to use art as therapy instead and began teaching herself to paint from Youtube tutorials. In today's episode, Beth joins hosts Amy and Denyse to discuss her journey from Youtube artist to international artist and the value of facing your fears. Beth explains that life is like a canvas, and we can recreate it and start fresh at any time. Once she realized her life was not serving her, it was time to start over with a blank canvas. Even though Beth was uncertain of where the future would lead, she took the leap anyway and doors began to open all around her. When she first started, she did not know anything about the professional art world. But there were many people who stepped up to help along the way. Beth went from living off food stamps in her friend's guest house to having her art on display in galleries worldwide after just one year. She attributes painting with helping her learn to face her fears, increase her self-confidence, and instill better time management skills. It can be really intimidating to make a big life change, especially in midlife. Beth was 38 years old when she found herself divorced without a career and no ideas on how she was going to become financially stable. Instead of giving up, she chose to face her fears and the universe rewarded her. When we are willing to make a leap of faith and not let fear hold us back from our dreams, we can achieve anything. Quotes “Once you take a jump, a leap of faith, it's like the universe rewards you.” (4:46-4:52 | Beth) “One year from the day I started, I had a piece at the Louvre as a modern art master.” (12:23-12:28 | Beth) “I didn't live my life for me. I lived my life for what I thought people expected from me or how it should be. And then it's like when you go through divorce, you go through death. You just don't care about the bullsh*t anymore.” (13:39-13:51 | Beth) “Changing the mental dialogue was huge to my success.” (18:50-18:55 | Beth) “Your life is your canvas. That's it. We can recreate, we can paint over, and start fresh.” (23:05-23:11 | Beth) Links: Connect with Beth Bowen: Instagram:https://www.instagram.com/iambethbowen/ Instagram: https://www.instagram.com/bethbowenart/ Recent Work To be Displayed in NYC: https://docs.google.com/document/d/1jnOgvo4cuI7-x103aX2W0VX9MoDZvLHy6cHTMUP41i0/mobilebasic?fbclid=IwAR3SYdexu93DjPqef82BFnPqU1RokOtfH4n13X1bRw1UZhrPy5aopGNzPm4 Amy & Denyse LOVE to network. Follow us on Instagram @midlifeatthemailbox and personally @AmyLAlex28 and @DenyseRabbat. Tag yourself listening to our episodes, make us laugh with your midlife moment or share your favorite episode of our show with your friends on Instagram and we will share it back to our community! #midlifemoment Do you enjoy our podcast? We'd love your help in growing our community. Please don't forget to rate, comment, and subscribe to Midlife at the Mailbox on Apple, Spotify, or wherever you listen to your favorite podcasts! One last note, both Amy & Denyse offer coaching services. Are you ready to promote your business or yourself? What about just a heads up that we have dropped a new episode? Sign up to receive emails from Midlife at the Mailbox. https://view.flodesk.com/pages/630a92cd2812b898e99a8f06 Thanks for listening, see you at the Mailbox! Podcast production and show notes provided by HiveCast.fm
ePub feed of Interpreter: A Journal of Latter-day Saint Faith and Scholarship
Review of Selwyn Kātene, ed., Let Their Light So Shine: Mormon Leaders in New Zealand (Wellington, NZ: Huia Publishers, 2021). “Foreword” by Charles A. Rudd (pp. vii–viii); “Preface” by Peter Lineham (p. ix–x); “Introduction” by Selwyn Kātene (pp. 1–3); “Contributors” (pp. 215–18); “Glossary” (and “Mormon Terms”) (pp. 219–21); “Index” (pp. 222–30). NZ $30.00 Hardbound. Abstract: […]
Review of Selwyn Kātene, ed., Let Their Light So Shine: Mormon Leaders in New Zealand (Wellington, NZ: Huia Publishers, 2021). “Foreword” by Charles A. Rudd (pp. vii–viii); “Preface” by Peter Lineham (p. ix–x); “Introduction” by Selwyn Kātene (pp. 1–3); “Contributors” (pp. 215–18); “Glossary” (and “Mormon Terms”) (pp. 219–21); “Index” (pp. 222–30). NZ $30.00 Hardbound. Abstract: […]
With all the talk about artificial intelligence and machine learning and generative AI and such, it's reasonable for marketers — especially those early in their careers — to ask, "Does… The post Big Trends: Does Marketing Have a Future? (Thinks Out Loud Episode 375) appeared first on Tim Peter & Associates.
On Episode 086, today's guest hails from California by way of Saint Vincent and the Grenadines. He's a Beatmaker, Collaborator, community activist, gardener, husband, father and more. Please welcome #ALGOC Algorythm-C to the show. Enjoy!During this episode, we chopped it up about his signature moniker, musical upbringings/inspirations (His father). Algorythm-C talked about his Myspace origins and making music for over 20 years. Algorythm-C names his Greatest Beats of All Time from Busta Rhymes "When Disaster Strikes" LP and Hipster Girl by Sango & Xavier Omär. He names his Beatmaker/Music Producer Superheros…The Neptunes, Pete Rock, and more. Algorythm-C started creating music with FL Studio (shout out to FL Gang) which remains his DAW of choice. He talks about his albums "Complexity", Metaphysical (a collaboration with Unorthadaks and Abstract (a collaboration with Lincoln Abraham). Algorythm-C talked about gardening and how the two worlds are similar. Algorythm-C left crazy jewels and inspiring words for Beatmakers and detailed what's in store for 2023.Algorythm-C's Recommendation:1. Start Listening To World Music2. Read Dilla Time: The Life and Afterlife of J Dilla, the Hip-Hop Producer Who Reinvented RhythmIntro Music: Now from Jewel Flips Vol. 1 by Brown JewelFeatured Music: Various tracks from Algorythm-C's Music Discography (Available Here)Social Media: @algorythmcWebsite: https://linktr.ee/AlgocSupport the showEdited, Mixed and Mastered by GldnmndPodcast Social Link: linktr.ee/TheRecShowPodcastNEW!!! TheRecShowPodcast Music Playlist Available Here
Enjoy our video series! Episode #71! Here's our NEW Costa Rica Good News Report YouTube Channel. Over 400 Short, Entertaining Videos that will get you excited about Costa Rica: https://www.youtube.com/@thecostaricagoodnewsreport/videos Here's a link to our Costa Rica Pura Vida Amazon Products Store! Happy Shopping! https://www.costaricagoodnewsreport.com/costaricaproductsamazon.html We appreciate your watching! I promise you will learn all you need to know about one of the happiest countries on the planet! Here's some links that will get you started in learning more about Costa Rica! Check out an amazing travel website catering to those travelers age 50 and over! Dozens of incredible expert contributors writing about so many destinations: https://www.travelawaits.com/author/william-licht/ Check out our COSTA RICA GOOD NEWS REPORT website! A great way to start every morning! Positive energy and good-news stories coming out of Costa Rica! Here's the link: https://www.costaricagoodnewsreport.com So many GOOD-NEWS stories coming out of Costa Rica. We'd love to share them with all of you! Way over 100 stories ready right now. Learn all about one if the Happiest Countries on the Planet. . Costa Rica! Here's a link: https://vocal.media/authors/william-skip-licht Here's a link to the US Embassy here in Costa Rica: https://cr.usembassy.gov/ --- Send in a voice message: https://anchor.fm/costa-rica-pura-vida/message
In this story, our adventurer discovers that pumpkin patches can hold some interesting surprises. Welcome to Midnight Slumber! We have a fun short story for you. Sit back, relax, enjoy this short story, and thanks for listening! Written and Narrated by Zack Miller. Follow us on Twitter @The_MNS_Podcast, Instagram @midnight_slumber_podcast, our YouTube Channel - Midnight Slumber, and Facebook – Midnight Slumber.
Are you walking for the long-term health benefits? During today's ten-minute walk, Dave talks about the day those are no longer abstract benefits. To help support the podcast tap HERE
Meditación sobre el Sermón de la Montaña: ayuno y mortificación, publicada en la página web del Opus Dei para el retiro mensual de marzo de 2023. Imagen. Title: Christ's sermon on the mount: The parable of the lily Abstract/medium: 1 print : lithograph.
We have an exciting announcement. Joining Craig Petty on tonight's podcast is no other than the man himself, Mr. Tyler Lunsford! Welcome back, Tyler. Craig and Tyler talk about Abstract Effects, Blackpool Magic, controversy regarding a ball holder, new products and much more.
Guest host Dr. Neeraj Agarwal and Dr. Christian Kollmannsberger discuss practice-changing abstracts that were presented at the 2023 ASCO Genitourinary Cancers Symposium, including results from the TALAPRO-2, PROpel, TRITON3, ARASENS, KEYNOTE-057, CheckMate 274, and CheckMate 9ER studies. TRANSCRIPT Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program, and professor of Medicine at the Huntsman Cancer Institute at the University of Utah, and editor-in-chief of the ASCO Daily News. Today, we will be discussing practice-changing abstracts and other key advances in GU Oncology featured at the 2023 ASCO Genitourinary Cancers Symposium. Joining me for this discussion is Dr. Christian Kollmannsberger, the chair of this year's ASCO GU. Dr. Kollmannsberger is a GU medical oncologist at the BC Cancer Vancouver Cancer Center and a clinical professor at the University of British Columbia. Our full disclosures are available in the transcript of this episode, and the disclosures of all guests on the podcast can be found on our transcripts at asco.org/DNpod. Christian, thank you for joining us on the podcast today. Dr. Christian Kollmannsberger: Thank you very much, Neeraj. It's a real pleasure to be here and have this discussion. Dr. Neeraj Agarwal: Thank you. So, Christian, the GU meeting featured remarkable progress in various GU malignancies. Could you please share some of the prominent topics that made the headlines this year and give us an overall feel of ASCO GU this year? Dr. Christian Kollmannsberger: Absolutely. I think it was a great meeting with over 5,800 attendees from more than 70 countries. And most of the attendees were in person, so it was a great event. ASCO GU is truly the premier global event to feature the very best of GU cancer research and treatment. The theme of this year's meeting was "Today's Science, Tomorrow's Treatment," and that was reflected in the novel scientific and clinical findings that were presented and will potentially lead to changes in our daily clinical practice. It also reminds us how quickly the development today is and how quickly novel scientific progress is immediately translated into clinical practice, particularly oncology. I was very impressed by the meeting's emphasis on diversity, interactivity, networking, multidisciplinary collaboration, and evidence-based care. We introduced several new features such as a “Meet the Professor session, a women's networking event, etc. And the first day really kicked off with a very rich focus on prostate cancer and much attention given to PARP inhibitors in our first session. As an example, LBA 17 was the first late-breaking abstract presented. And congratulations to you, Neeraj, on delivering this exciting data on the TALAPRO-2 trial, which were eagerly awaited. Let's start with that. Can you tell us about this trial? Dr. Neeraj Agarwal: Yes, of course. So the TALAPRO-2 trial was a phase 3 randomized trial where patients in newly diagnosed metastatic CRPC settings were randomized to standard of care enzalutamide plus placebo versus enzalutamide plus talazoparib PARP inhibitor. And as we know, Christian, the rationale has been that dual inhibition of PARP and AR may enhance the efficacy of each. And there's a laboratory preclinical rationale and based on which other studies have been done in the past. So, without getting into too much detail into the rationale for the trial, I'll come right to the results of the trial. So, this was the first-line mCRPC setting where rPFS was the primary endpoint as assessed by the independent radiology assessment. And in this trial, patients were recruited regardless of the homologous recombination repair gene alterations. So, patients were recruited and they were prospectively tested for whether they had these HRR gene alterations or not, but all comer population was included in this trial. And after a median follow-up of approximately 23 months, the trial read out, and we found that trial made the primary endpoint was improved radiographic progression-free survival with the rPFS being about 22 months in the enzalutamide arm and not reached in the combination arm with a 37% reduction in risk of progression or death. If you look at the subgroup analysis of patients who were HRR+, there was a 54% reduction risk of progression or death. If you look at patients who were stratified in HRR- or unknown group, there was a 30% reduction risk of progression or death. If you specifically look at an exploratory analysis we did to look for patients who were HRR- by prospective tumor tissue testing; there was a 34% reduction in risk of death with a hazard ratio of 0.66 favoring the combination arm. So overall, the rPFS primary endpoint was met in all groups. We also see significant delay in PSA progression in the combination arm by more than nine months. We also see delays in the time to cytotoxic chemotherapy. We saw delay in progression or death on subsequent neoplastic therapy after the protocol treatment. We saw delays in deterioration of quality of life and global health status. All these were significant and happened on the talazoparib plus enzalutamide arm. So overall, if you look at the totality of the data, these all favored the combination of talazoparib plus enzalutamide compared to enzalutamide alone. I want to highlight that overall survival is immature at 31% maturity with a hazard issue of 0.89, currently favoring enzalutamide plus talazoparib. But we'll have to look at more mature data as time passes. Dr. Christian Kollmannsberger: Wow. Thank you, Neeraj. So, it sounds like that was a very positive trial, and it's potentially practice-changing. One of the concerns is always safety and toxicity. So can you tell us whether there were any new safety signals, and can you tell us more about the common adverse events that were noticed in TALAPRO-2? Dr. Neeraj Agarwal: No discussion is complete without talking about safety results, so I'm glad you asked me, Christian. The most common dose-affecting toxicity, if you will - so toxicities which led to dose modification and dose discontinuation of talazoparib were cytopenias, as we expect from this class of agents. So anemia, neutropenia, thrombocytopenia, these were the common toxicities. In fact, rate with anemia was 46.5%. Neutropenia and cytopenia were much less common. I would like to highlight one fact which also came up during the discussion section after our oral presentation. The qualifying criteria for entry in this trial was a hemoglobin of 9-gram percent. And 49% of patients had grade 1 to 2 anemia at baseline, that is before starting treatment with talazoparib. So, we knew that if you mandate dose reduction, a lot of patients will not get adequate dosing of talazoparib. So, we waited for grade 3 anemia and then instituted dose reduction. And that I thought personally was a good strategy because the grade 3 anemia happened after a median duration of three months, 3.3 months to be more precise. And then, these patients underwent protocol-mandated dose reduction, following which the dose discontinuations were quite low actually. Only 8.3% patients discontinued talazoparib because of anemia, and the median dose intensity or median relative dose intensity of talazoparib in the talazoparib arm remained quite high at more than 80%, which translates to a talazoparib dose of 0.4 milligram daily when the starting dose was 0.5 milligram. So those were the hallmark of toxicities. I do like to mention that those grade 3, 4 toxicities which are more known to affect the quality of life of our patients, such as grade 3, 4 anorexia, fatigue, nausea and vomiting, they were quite rare, happening in 1 to 4% patients who were on talazoparib. So overall, regarding the side effects, they were manageable, there were no new safety signals, and we could maintain adequate talazoparib dosing with dose reduction, which happened quite early during the protocol treatment. Dr. Christian Kollmannsberger: Thank you, Neeraj. Very impressive results indeed. The patient population included in TALAPRO-2 was very similar to those included in the PROpel phase 3 trial, which tested the combination of abiraterone and olaparib in the first-line mCRPC setting. So, I'd like to just mention that we also saw LBA16 on the PROpel study, which was the final overall survival in PROpel, which was presented by Noel Clarke. So PROpel, as you know, was a randomized phase 3 trial evaluating efficacy and safety of olaparib plus abiraterone versus placebo plus abiraterone as first-line therapy for mCRPC in the first-line metastatic castration resistance setting. The enrollment in that study was independent of known defects in the homologous recombination repair gene pathway in contrast to other studies, such as MAGNITUDE, which tested the biomarker upfront. A total of 796 patients were randomly assigned to either olaparib plus abiraterone or placebo plus abiraterone. And we saw similar results, significant radiographic progression-free survival with olaparib plus abiraterone in PROpel, which was the primary endpoint similar to TALAPRO-2, and that was published last year in the New England Journal of Medicine Evidence. Now, this abstract presented here at ASCO GU reported on overall survival with an overall survival majority of 47.9% and showed that with the addition of the PARP inhibitor olaparib to abiraterone, a statistically non-significant but clinically meaningful improvement in overall survival of about seven months were achieved compared to standard of care in abiraterone alone. The numbers were 42.1 versus 34.7 months in the all-comers population of patients in the first-line mCRPC setting. Importantly, I think the median overall survival of more than 42 months really represents the longest reported median overall survival thus far in a phase III trial for first-line metastatic castration-resistant prostate cancer. Although the median overall survival for the non-HRR group remains not statistically significant, with a hazard ratio of 0.89. Dr. Neeraj Agarwal: Such a great synopsis of the PROpel result data. Thank you, Christian, for highlighting these results. As we know, the combination is already approved by the EMA, the European Medical Agency, for patients in the first-line mCRPC setting who are not candidates for docetaxel chemotherapy. If this combination is approved by the FDA, we may have one more therapeutic option for our patients in first-line mCRPC. So, just continuing on the PARP inhibitors, there was one more oral presentation with PARP inhibitor rucaparib by Dr. Alan Bryce from the Mayo Clinic, Arizona. This was Abstract 18 on the primary result of the TRITON3 trial. So to complete our PARP inhibitor section, I would like to summarize the result of the TRITON3 trial, which was a randomized phase III trial evaluating rucaparib versus physician choice, which notably included docetaxel in addition to abiraterone or enzalutamide in patients with chemotherapy-naive mCRPC with BRCA1, BRCA2 or ATM alterations. These patients had disease progression after having one novel hormonal therapy, or we call them second-generation androgen pathway inhibitors in any setting. So these patients had to have disease progression on a novel hormonal therapy. In the BRCA subgroup and the subsequent intention to treat the population, the primary endpoint tested first was radiographic progression-free survival, and overall survival was the key secondary endpoint. The subgroup of patients with BRCA-altered disease had a median rPFS of 11.2 months with rucaparib compared to 6.4 months with physician choice of treatment - looks like almost doubling of the rPFS with the rucaparib. In the overall ITT population, median rPFS was 10.2 months with rucaparib and 6.4 months with the physician's choice of treatment. Although the overall survival data are immature, we still see a trend for improved overall survival with rucaparib. Regardless, the study clearly demonstrates the value of rucaparib for treating BRCA1 and BRCA2-altered mCRPC after disease progression on an androgen receptor pathway inhibitor. So these were the impressive results from the TRITON3 trial. But before we switch to non-prostate abstract, I would like to complete the prostate cancer discussion by talking about the Abstract 15, which was based on the results of the ARASENS trial presented by Dr. Maha Hussain. As we know, ARASENS is a randomized phase 3 trial evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy plus docetaxel versus androgen deprivation therapy or ADT plus docetaxel. So the triplet of ADT plus darolutamide plus docetaxel being compared to ADT plus docetaxel chemotherapy in patients with newly diagnosed metastatic castration-sensitive prostate cancer. A total of 1,300 patients were randomly assigned to the doublet versus triplet. As presented in the last ASCO GU meeting exactly one year ago, the primary endpoint of the study was met with a significant improvement in overall survival and a 32% reduction in risk of death for patients on the triplet therapy with ADT plus docetaxel plus darolutamide versus ADT plus docetaxel chemotherapy. So triplet therapy was already approved based on these data. The abstract presented by Dr. Hussain this year is a post-talk analysis where Dr. Hussain and colleagues investigated the impact of triplet therapy across patients with high volume versus low volume per chartered criteria and higher risk versus low risk using latitude trial criteria. And investigators knew that these results would be highly attractive to practicing oncologists who are now choosing treatment based on volume of disease or risk of disease, more commonly, volume of disease. So, let's come to what was presented this ASCO GU. So, after 1,305 patients in ARASENS, the majority had high-volume disease and high-risk disease. Among patients with high-volume disease, the addition of darolutamide reduced the risk of death by 30% compared with ADT and docetaxel, with a hazard ratio of 0.69. In the risk groups, the addition of darolutamide seems to favor both high-risk and low-risk groups. Among patients with low-volume disease, there was a trend towards improvement in overall survival with the addition of darolutamide, but it did not reach statistical significance. The great news was that there was no new safety signal. So, to summarize these data, the triplet of darolutamide plus ADT plus docetaxel showed superior overall survival compared to doublet of ADT plus docetaxel, with an important caveat that triplet was not compared with any of the modern doublets of ADT plus a second generation androgen receptor pathways inhibitor such as abiraterone, apalutamide, or enzalutamide, or even darolutamide. So, I wish there was a third arm of ADT plus darolutamide. Having said that, triplet can be considered a standard of care now based on these data for patients with metastatic hormone sensory prostate cancer, where we would be using ADT plus docetaxel chemotherapy. And from this meeting data, this efficacy of triplet can be applied to high-volume disease and all risk disease. And we just need more time to see how the data pans out in low-volume patients with metastatic hormone-sensitive prostate cancer. Dr. Christian Kollmannsberger: Yes, I completely agree, Neeraj. I think all the data presented in these abstracts are really impressive and will impact our daily clinical practice and our patients more or less immediately. I think the use of PARP inhibitors, whether as a monotherapy or in combination with androgen receptor pathway inhibitors, as well as now the option of triplet therapy in the metastatic castration sensitive setting really offer patients with metastatic prostate cancer new treatment strategies and most importantly, improved survival outcomes. And it is impressive to see how we have pushed the prognosis and the outcomes for our patients with prostate cancer, I would say, in the last five to ten years. And similar to last year, I think the entire Prostate Cancer Day at ASCO GU 2023 was full with impressive data and featured dynamic content throughout the day. Dr. Neeraj Agarwal: Indeed. So, let's move on to bladder cancer. Christian, what are your key takeaways from the bladder cancer studies presented at the meeting? Dr. Christian Kollmannsberger: I think there were interesting abstracts in both the non-muscle-invasive and the muscle-invasive setting and the metastatic setting. So, for example, Abstract 442 was presented by Dr. Andrea Necchi on the cohort B of the phase 2 KEYNOTE-057 trial. As a background here, the standard treatment for high-risk non-muscle-invasive bladder cancer involves transurethral resection of the bladder tumor, a TURBT, followed by intravesical BCG therapy to eradicate any residual disease. And patients who fail to adequately respond to BCG are usually recommended to undergo radical cystectomy. So in the cohort B of the phase 2 KEYNOTE-057 trial that investigated the safety and efficacy of pembrolizumab as a single agent for patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer who were ineligible or declined to undergo radical cystectomy, enrolled patients received standard-dose pembrolizumab of 200 milligrams every three weeks for up to 35 cycles. So very common as we do it with other disease sites. And at a median follow-up of 45.4 months, the primary endpoints of disease-free survival at twelve months was 43.5%. The median disease-free survival duration was 7.7 months. These are encouraging results, and we should keep in mind that a radical cystectomy has immense impact on our patients' quality of life. So I think it is important that we do these trials. Now in order to address potential biases in this phase II trial, such as the underlying heterogeneity of transurethral resection of bladder tumor quality, and to obtain a more comprehensive understanding of pembrolizumab's efficacy relative to a particular control group, we need further evaluation of pembrolizumab in a randomized trial before we can really go for regulatory approval. But overall, I think for the first time in a long time that we seem to be able to move the needle in non-muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Christian, for this great overview. Could you please also share the findings presented by Dr. Matt Galsky on Abstract 443? Dr. Christian Kollmannsberger: Of course, Neeraj. Abstract 443, presented by Matt Galsky, reported the extended follow-up results from the CheckMate 274 trial, which looked at another very important field where we haven't made that much progress, which is the adjuvant setting. And CheckMate 274 examined adjuvant nivolumab compared to placebo for patients with high-risk resected muscle-invasive urothelial carcinoma. In this trial, nivolumab was given at 240 milligrams every two weeks or placebo every two weeks for up to one year of treatment. After following up with patients for a median of 36.1 months, the study found that those who received nivolumab had a median DFS of 22 months compared to only 10.9 months for those who received placebo among the ITT patients. So basically, a doubling of the DFS with the addition of adjuvant nivolumab. The results were particularly notable for patients with high PD-L1 expressions or PD-L1 expression of 1% or more, as those who are treated with nivolumab had a median DFS of 52.6 months, which was six times higher than the DFS in the control group where patients received placebo, which was only 8.4 months. And I think that is truly impressive. One year of adjuvant therapy with nivolumab continues to show a sustained disease-free survival benefit over a period of three years in both the ITT and the PD-L1-high patient population. In my view, these results reinforce the utility of nivolumab in the adjuvant urothelial carcinoma setting after surgery. And it will be interesting to see how the overall survival pans out in this study. So, Neeraj, moving on to kidney cancer, what were your key takeaways from these studies on kidney cancer presented in this meeting? Dr. Neeraj Agarwal: So, there were exciting results presented from multiple studies in this area as well. For example, Abstract 603 presented by Dr. Mauricio Burotto, senior author was, Dr. Toni Choueiri on the three-year follow-up from the phase 2 CheckMate-9ER trial. So, in this trial, patients were randomized one-to-one to nivolumab 240 milligrams every two weeks, plus cabozantinib 40 milligrams daily versus sunitinib 50 milligrams daily for four weeks, and it was a six-week cycle for sunitinib until disease progression or unacceptable toxicity. So this was the design of the phase 3 CheckMate-9ER trial. And after a median follow-up of three years, the benefit of nivolumab plus cabozantinib remained consistent with previous follow-ups. So, as we know, these data have been presented in the past, also published in the New England Journal of Medicine. But this meeting was a clear follow-up of these data. Notably, the median overall survival of patients treated with cabozantinib plus nivolumab in the ITT population, which included all favorable intermediate and poor IMDC score patients, was significantly improved at 49.5 months compared to 35.5 months in the sunitinib arm. It is so heartening to see that median overall survival breaching the four-year mark in our patients with metastatic RCC in a consistent fashion. We saw similar data with the combination of ipilimumab plus nivolumab recently. And as these trials are maturing, we are probably going to see more combinations breaching this four-year mark. So importantly, no new safety signals emerged with the additional follow-up in either arm. And I think these results provide further support for the use of cabozantinib plus nivolumab as a first-line treatment option for patients with metastatic or advanced renal cell carcinoma. Dr. Christian Kollmannsberger: Indeed, I think it is extremely impressive what we've seen over the last 15 years in metastatic kidney cancer, going from a median overall survival of about a year to now more than four years. I think that is a great achievement, and we can see it on a daily basis in our clinical practice. Now, before we wrap up, I would like to highlight another potentially practice-changing trial, LBA602, which titled, “Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma: The ZIRCON Trial” presented by Dr. Brian Shuch. The background of this is that the detection of renal masses poses a challenge due to the limitations of diagnostic options such as imaging and biopsy. And we often, in clinical practice, are confronted with "What exactly is this?" And what's even more importantly, “What's the histology of this?” And a non-invasive, accurate method is needed for pre-treatment risk stratification. Girentuximab, a monoclonal antibody that targets carbonic anhydrase IX expressed on clear cell renal cell carcinoma, can obviously now aid in the differentiation between clear cell renal cell carcinomas and other renal lesions when radiolabeled with this new agent. The ZIRCON trial was open-label and designed to include patients with renal masses up to 7 cm in size or clear tumor stage cT1 who were scheduled for partial nephrectomy within 90 days of planned TLX250-CDx administration. The enrolled patients received a single intravenous dose of girentuximab on day 0 and underwent FDG PET/CT imaging on day 5 before their scheduled surgery. And the co-primary endpoints were to assess the sensitivity and specificity of girentuximab PET/CT imaging for detecting clear cell renal cell carcinoma in patients with indeterminate renal masses, with histology as the reference standard, which I think is a great way to test these agents because you get 100% validation. In the primary analysis of 284 patients, the average sensitivity and specificity across all three central readers were 86% and 87%, respectively, exceeding the prespecified thresholds. The positive and negative predictive values were 93.4% and 78%, respectively. And with very few related adverse events reported, the study affirms that girentuximab PET/CT is safe and effective in identifying clear cell renal cell carcinoma in patients with indeterminate renal masses. And the findings hold potential for developing optimal management strategies for patients with indeterminate renal masses. I think this is important that we add a non-invasive method to this because we are confronted on a regular basis with patients who either cannot tolerate a biopsy or where the biopsy is indeterminate. And this could potentially be a great tool to help us with our pre-treatment planning of our treatment strategy. Dr. Neeraj Agarwal: Wow. So, it looks like a new PET scan using a unique tracer and antibody to detect the clear cell renal cell carcinoma with high specificity and sensitivity. It reminds me of drawing a crude analogy from the PSMA PET scan in prostate cancer. And hopefully, we will be able to use these newer scans that we call TLX250-CDx PET/CT scan. I hope they have a simpler name for this very soon. Or maybe follow up for patients who had kidney cancer, localized kidney cancer taken out by radical surgery, and then we are following them. And sometimes, we don't know if a small lung nodule is metastatic or not. And these kinds of imaging studies may help us down the line in monitoring those patients as well. So indeed, very exciting progress not only in the therapeutic area now but also in diagnostic fields at this GU ASCO. So with that, we have seen multiple abstracts on prostate, bladder, and kidney cancer with real impact on how we practice medicine. Thank you, Christian, for sharing your insight with us today. It is an exciting time in GU Oncology, and we appreciate you taking the time to contribute to the discussion. Thank you so much. Dr. Christian Kollmannsberger: Thank you, Neeraj, thank you for having me. And I completely agree it remains an exciting time in GU oncology. Dr. Neeraj Agarwal: And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcripts of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Neeraj Agarwal @neerajaiims Dr. Christian Kollmannsberger Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas Dr. Christian Kollmannsberger: None disclosed
Christopher McDougal's latest book, Born To Run 2, revisits the barefoot and minimalist movement that upended the world of running over a decade ago when he published his first book Born To Run in 2009. But what does the latest research say and is running barefoot the key to running nirvana?SHOW NOTES:Sean Ingle's report after UK Athletics announced a “non-policy” recognition of the trans women issue and were corrected by EHRC: The statement by the Equality and Human Rights commissionThe Peter Bol doping story, as submitted by Patron Joshua StaceyThe Connor Benn doping clearance story, with much to be discussed and determinedThe WADA study on clomiphene in eggs: https://www.tandfonline.com/doi/abs/10.1080/19440049.2021.1949497The twitter thread that speculates about the use of biomechanics as a way to identify a doperThe article that is skeptical about barefoot runningStudy on stiffness of tendons in cushioned vs minimalist runnersOne of the reviews showing no injury risk difference between shod and barefoot runnersStudy showing successful transition to barefoot running in 71% of runners with a 20 week transition programmeNic Tam's study on individual responses to barefoot runningNic's second paper on how individuals respond to a barefoot running programmeNic's third paper on the effect of fatigue on biomechanics when barefoot vs shod Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.
WORM "PUTREFYING SWAMP MISTS AT DUSK"ICD10 "CAN'T SEE OUT"LYKOTONON "THAT WHICH STARES IN KIND"EL-P "THE NANG, THE FRONT, THE BUSH, & THE SHIT"THE TAJ MAHAL TRAVELERS "BETWEEN 7:03-7:15PM"CLUSTER "IM SUDEN"BRUNO SPOERRI & RETO WEBER "COMSIC SAMBA"FLUENCE "A FEW REASONS TO STAY - A FEW REASONS TO SPLIT"
Welcome to a brand new episode of the ¿Quién Tú Eres? podcast, where we explore the conflict we often face between "professionalism" & being our authentic selves. This week, we have the pleasure of speaking with Joshua Encarnacion. Joshua is a 1.5 generation Dominican-American, and a proud Afro-Latino…with his heart set on growing and helping people grow into their full potential. He's helped build 3 tech-industry startups and worked in training & recruiting roles for big tech companies Uber & Google. Born in Manhattan, NY, and raised in Lawrence & Springfield, MA, Joshua has nothing but love for his folks and the people he's met along his journey as a lifelong learner consisting of a lot of sports, math, reading, perreo, bachata, y cafe bustelo. Throughout his career, he's serviced the following organizations: Google, Facebook, Amazon, Microsoft, UBER, Airbnb, Netflix, Pandora, Slack, Twitter, Pinterest, Earnest, Gusto, Affirm, Abstract, Simply Business, Thumbtack, Yelp, Asana, Lyft, Atlassian, Tinder, First Round Capital, Kapor Center, General Assembly, Hackbright, Latinas in Tech, NextPlay, CODE2040, Hack The Hood, CODE Tenderloin, The Justice Collective, Change Catalyst, Techqueria, Big Nerd Ranch, and MANY more unlisted. He's coached people through various challenges by helping them grow the emotional intelligence and high-performance habits necessary to create their own professional success, which is a passion of his. --- Send in a voice message: https://anchor.fm/quientueres/message Support this podcast: https://anchor.fm/quientueres/support
From the very beginning of our species, musical communication has been a key component of prosocial, cooperative behaviors, acting as a counterweight to the other, newly evolved human communication system—language. It is about why music continues to be an essential part of human cognitive well-being in the twenty-first century. From the Abstract of “Music, Evolution, … Continue reading "Episode 138: Evolving the Musical Mind with Dr. Alan Harvey"
ORPHIUS JONES ALSO KNOWN AS ZULU BUTTERFLY OR DJ ZU , HAS BEEN A SUPPORT BESIDE MANY RAP ARTISTS, SUCH AS BROTHER JAY FROM X-CLAN, ABSTRACT RUDE, ACEYALONE, MEDUSA- THE GANGSTA GODDESS, AND A HOST OF OTHERS...HE IS NOW KNOWN FOR POPPIN OFF THE MOST ECLECTIC , BALLSY BLEND OF MUSIC TO GROOVE TO. FIND OUT WHAT MAKES HIM TICK, AND HIS INFINITE WISDOMS ON THE TOMEICKO SHOW. --- Send in a voice message: https://anchor.fm/tomeickoshow/message
It was great to have Tennis Abstract's Jeff Sackmann join the pod as we discuss Jeff's recent 128 best players in the world list, which includes a combination of both men and women. Jeff goes into detail on certain parameters, and which factors weigh more than others. Enjoy this fascinating discussion with Jeff. Find "Court-Side with Beilinson Tennis": Tennis Channel Podcast Network: https://www.tennis.com/pro-game/podcasts/10/ Facebook: https://www.facebook.com/courtsidewithbeilinsontennis Instagram: https://instagram.com/court_side_with_beilinson Twitter: https://twitter.com/Court_Side_w_BT Website: https://www.beilinsontennis.com/
In this episode Colin we discuss his latest picture, doing abstract and impressionism using pastel pencils, and offer advice to our students on pictures they're doing.
In this story, our adventurer has some uninvited guests show up. Welcome to Midnight Slumber! We have a fun short story for you. Sit back, relax, enjoy this short story, and thanks for listening! Written and Narrated by Zack Miller. Follow us on Twitter @The_MNS_Podcast, Instagram @midnight_slumber_podcast, our YouTube Channel - Midnight Slumber, and on Facebook – Midnight Slumber.
In this episode, Wes and Todd sit down with Digital and Mixed Media Artist, Billy Ludwig. Billy discusses the art scenes in Miami and New York, Art Basel, art fairs, digital work, photoshop, mixed media, process Lucasfilm, compositing images, Star Wars vs. World War II, research, the importance of authentic representation in his work, getting flagged on Instagram, being invited to Okinawa, Japan by the Marine Corps, Vaudeville Phantoms, Galactic Samurais, art in his youth, having an addiction to ideas & being creative, music, the compulsion to create, the Pentagon, Washington, D.C., emoting through art, abstract art, Thirteenth Floor, and rules.Join us for a sensational conversation with Billy Ludwig.Check out Billy's work at his website www.billyludwig.netFollow Billy Ludwig on social media:On Instagram - www.instagram.com/billyludwig/@billyludwigOn Facebook - www.facebook.com/billyludwigofficialCheck out the Thirteenth Floor website at www.thirteenthfloor.usFollow Thirteenth Floor on social media:On Instagram – www.instagram.com/thirteenthfloor/@thirteenthfloorOn Facebook - www.facebook.com/thirteenthfloor
Washington state produces a lot of scientific research. And all that observation, data collection, and testing of hypotheses can be hard to wade through for everyday, average, non-scientists.So we're taking time to break down some recent findings coming out of our Washington braintrust as part of a segment we're calling, “The Abstract.”Today we're exploring new revelations about how animals adapt to climate change – and what that tells us about the future of ecosystems, including an unwelcome and foul-smelling new neighbor here in the Pacific Northwest, and an adorable Patagonian predator.We can only make Soundside because listeners support us. Make the show happen by making a gift to KUOW: https://www.kuow.org/donate/soundside
THE BLOWFLYS "FUNKY IN THE HOLE"ALAIN GORAGUER "POST SCRIPTUM/POST COITUM"SANDY SAMUEL "(I LIKE) SADO-MUSIC"KOOL KEITH "I WANNA PLAY"PATRICK COWLEY "BORE & STROKE"THE PLUGZ "ELECTRIFY ME"KLAUS SCHULZE "NOWHERE NOW HERE"
En este episodio, hablamos en detalle sobre el caso de espionaje en teléfonos inteligentes Xiaomi Redmi, Oppo Realme y OnePlus.Un estudio reciente realizado por investigadores de la Universidad de Edimburgo y del Trinity College Dublín descubrió que estos dispositivos recopilaban y transmitían grandes cantidades de datos personales de los usuarios a varios servidores sin su consentimiento, lo que ha generado preocupación sobre la privacidad y la seguridad de los usuarios.Discutimos los detalles de este estudio, incluyendo cómo el spyware está oculto en ventanas emergentes y anuncios que los usuarios pueden ver mientras usan sus teléfonos. También explicamos cómo se puede desactivar la opción de publicidad o anuncios en las versiones de Android MIUI, Realme UI y Oxygen OS para evitar la recopilación innecesaria de datos por parte de terceros. Este episodio es imprescindible para cualquiera que quiera proteger su privacidad en el mundo de los teléfonos inteligentes.Todas las músicas usadas en este episodio están autorizadas con licencias Canva y Audiio: https://ref.audiio.com/3n4qg4x3 (usa el código "SAVE70" para ahorrar el 70%) El estudio del que hablamos fue realizado por tres investigadores de la Universidad de Edimburgo y del Trinity College Dublín. https://arxiv.org/pdf/2302.01890.pdf El título del documento es ““La privacidad del sistema operativo Android bajo el microscopio - Un cuento del Este” Y está firmado por:Haoyu Liu - The University of edinburgh Edinburgh, United Kindgom haoyu.liu@ed.ac.ukPaul Patras - The University of edinburgh Edinburgh, United Kindgom paul.patras@ed.ac.ukDouglas J. Leith - Trinity College Dublin Dublin, Ireland Doug.Leith@tcd.ieEsta es la traducción de parte del Abstract del documento:"Descubrimos que un número alarmante de aplicaciones del sistema, proveedores y terceros preinstalados se les otorgan privilegios peligrosos". La respuesta de Oppo y Realme a Xataka México sobre esta información: https://www.xataka.com.mx/celulares-y-smartphones/xiaomi-oppo-oneplus-tienen-software-espia-sus-smartphones-que-recolecta-informacion-usuarios-permiso-estudioEntra tú también a nuestro grupo Telegram en ElSiglo21esHoy.com
En este episodio, hablamos en detalle sobre el caso de espionaje en teléfonos inteligentes Xiaomi Redmi, Oppo Realme y OnePlus.Un estudio reciente realizado por investigadores de la Universidad de Edimburgo y del Trinity College Dublín descubrió que estos dispositivos recopilaban y transmitían grandes cantidades de datos personales de los usuarios a varios servidores sin su consentimiento, lo que ha generado preocupación sobre la privacidad y la seguridad de los usuarios.Discutimos los detalles de este estudio, incluyendo cómo el spyware está oculto en ventanas emergentes y anuncios que los usuarios pueden ver mientras usan sus teléfonos. También explicamos cómo se puede desactivar la opción de publicidad o anuncios en las versiones de Android MIUI, Realme UI y Oxygen OS para evitar la recopilación innecesaria de datos por parte de terceros. Este episodio es imprescindible para cualquiera que quiera proteger su privacidad en el mundo de los teléfonos inteligentes.Todas las músicas usadas en este episodio están autorizadas con licencias Canva y Audiio: https://ref.audiio.com/3n4qg4x3 (usa el código "SAVE70" para ahorrar el 70%) El estudio del que hablamos fue realizado por tres investigadores de la Universidad de Edimburgo y del Trinity College Dublín. https://arxiv.org/pdf/2302.01890.pdf El título del documento es ““La privacidad del sistema operativo Android bajo el microscopio - Un cuento del Este” Y está firmado por:Haoyu Liu - The University of edinburgh Edinburgh, United Kindgom haoyu.liu@ed.ac.ukPaul Patras - The University of edinburgh Edinburgh, United Kindgom paul.patras@ed.ac.ukDouglas J. Leith - Trinity College Dublin Dublin, Ireland Doug.Leith@tcd.ieEsta es la traducción de parte del Abstract del documento:"Descubrimos que un número alarmante de aplicaciones del sistema, proveedores y terceros preinstalados se les otorgan privilegios peligrosos". La respuesta de Oppo y Realme a Xataka México sobre esta información: https://www.xataka.com.mx/celulares-y-smartphones/xiaomi-oppo-oneplus-tienen-software-espia-sus-smartphones-que-recolecta-informacion-usuarios-permiso-estudioEntra tú también a nuestro grupo Telegram en ElSiglo21esHoy.com
Guest host Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss several crucial studies that will be presented at the 2023 ASCO Genitourinary Cancers Symposium, including ARASENS, TRITON3, and others in prostate cancer, as well as novel therapies in mRCC and urothelial carcinoma. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I'm the director of the Genitourinary Oncology Program, a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. I'm delighted to welcome Dr. Jeanny Aragon-Ching, a medical oncologist and the clinical program director of the Genitourinary Cancers Program at the Inova Schar Cancer Institute in Virginia. Today we will be discussing key abstracts in genitourinary oncology that will be featured at the 2023 ASCO Genitourinary Cancers Symposium. Our full disclosures are available in the show notes, and disclosures for all guests on the podcast can be found on our transcripts at asco.org/podcasts. Jeanny, it is great to have you on the podcast today. Dr. Jeanny Aragon-Ching: Thank you so much, Dr. Agarwal, for having me. Dr. Neeraj Agarwal: So Jeanny, let's begin with Abstract 15 on the update on the ARASENS trial, which Dr. Maha Hussain will present [at the meeting]. In March ‘22, as we know, almost a year ago, the results of the ARASENS trials were published in the New England Journal of Medicine. Darolutamide, which is an AR signaling inhibitor plus androgen deprivation therapy plus docetaxel chemotherapy, significantly reduced the risk of death by 32.5% versus placebo plus ADT plus docetaxel. The effect of triplet therapy, including darolutamide on overall survival, was consistent across prespecified subgroups. However, survival outcomes by disease volume were not reported at the time. Can you please tell us about Abstract 15? Dr. Jeanny Aragon-Ching: Yeah, thank you so much, Neeraj, I would be happy to. So, this new data is actually very crucial for all clinicians. The title of this abstract is “Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study.” So, as a quick reminder, in this trial, patients were randomized 1:1 to the standard dose of darolutamide 600 milligrams twice daily or placebo with ADT and docetaxel in the metastatic hormone-sensitive prostate cancer setting. Now remember, too, high volume disease was defined per the charted criteria, which is visceral metastases and/or four or more bone lesions, of which at least one or more has to be beyond the vertebral column or pelvis. 8And high-risk disease was actually defined per the LATITUDE criteria, which is any two or more of the following three factors: Gleason scores eight or more, bone lesions that are three or more, and the presence of measurable visceral metastases. Of all the 1,305 patients, 77% of them were actually classified as having high-volume disease, and 70% of them had high-risk disease. So, in both of these high-volume and low-volume disease patients, the triplet therapy darolutamide, ADT, and docetaxel actually improved overall survival and hazard ratio was 0.69 and 0.68, respectively. Compared to the placebo and ADT, and docetaxel arm. So overall survival improvement was also significant in patients across all risk, high-risk, or low-risk disease. Dr. Neeraj Agarwal: So, Jeanny, this is great news. So, the main message from this abstract for our audience is that triplet therapy of darolutamide plus docetaxel plus ADT is more efficacious than the doublet of ADT plus docetaxel chemotherapy, regardless of disease volume or risk status. One important caveat I would like to note is that triplet therapy with the darolutamide was not compared with the doublet therapy of ADT plus darolutamide or any androgen receptor signaling inhibitor such as abiraterone or apalutamide or enzalutamide, all of which have shown benefit consistently, regardless of volume status, and in the case of abiraterone, also in the context of high-risk disease setting, as we saw in the LATITUDE trial. Dr. Jeanny Aragon-Ching: Absolutely. I agree with that, Neeraj. Those are important points to consider. Now, moving on to a different setting in prostate cancer across the disease continuum, let's discuss Abstract 18, titled “Rucaparib for Metastatic Castrate-Resistant Prostate Cancer.” This is TRITON3 entering overall survival and efficacy of rucaparib versus docetaxel or second-generation engine pathway inhibitor therapy, which will provide us with some additional data regarding overall survival. Neeraj, based on this new abstract, can you tell us more about TRITON3, which will be presented by Dr. Alan Bryce and colleagues from the Mayo Clinic Arizona? Dr. Neeraj Agarwal: Of course. So TRITON3 is a randomized multicenter open-label phase 3 trial where rucaparib was compared with the physician choice of docetaxel chemotherapy or abiraterone or enzalutamide in those patients who had not received chemotherapy in the metastatic castration-resistant prostate cancer setting, and they had to be progressing on a prior androgen receptor signaling inhibitor in any setting prior. So, they just had to have disease progression either in the hormone-sensitive setting or CRPC setting on one of the AR inhibitors, and they had to have a BRCA1, BRCA2, or ATM alteration. So, in this context, these patients were randomized to rucaparib versus physician's choice of agent, which could again be docetaxel chemotherapy, abiraterone, or enzalutamide. So, OS maturity is 54% in BRCA group and 59% in the intention to treat population. In BRCA1 and BRCA2 populations, radiographic PFS, which was the primary endpoint, was 11.2 months in rucaparib group and 6.4 months in the physician choice arm. In the intention to treat population where you include all patients BRCA plus ATM patients, ATM positive patients. Radiographic PFS was 10 months almost versus 6.4 months with standard of care. And both were statistically significant as well as clinically meaningful improvement in the radiographic progression-free survival with rucaparib over physician's choice of either docetaxel or enzalutamide, or abiraterone. I would like to note that most frequent toxicity which we see with this group of agents is most frequent grade III or more toxicity was anemia, which was present in approximately 24% patients treated with rucaparib. Dr. Jeanny Aragon-Ching: Yeah. This is a really exciting update, Neeraj. What do you think is the key takeaway from this abstract? Dr. Neeraj Agarwal: The key takeaway is that TRITON3 trial met its primary endpoint, and rucaparib significantly improves radiographic progression-free survival in BRCA mutation-positive patients or BRCA ATM-positive patients. Overall survival is still immature, and these results further establish rucaparib as one of the standard of care options in those patients who have metastatic CRPC with prior treatment with the AR signaling inhibitor and who harbor one of the BRCA mutations or BRCA NAT mutations. So, Jeanny, before moving on to the renal cell carcinoma section in this podcast, there is an Abstract in prostate cancer talking about correlation between the source of funding and disparities among patients with advanced prostate cancer. So, I'm referring to that Abstract 40, titled “Source of Funding and Enrollment Disparity in Prostate Cancer Clinical Trials.” I thought this was an interesting abstract. Could you please tell us more about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in Abstract 40, Dr. Riaz and Dr. Bryce, and colleagues actually looked at phase II and III clinical trials that involved prostate cancer patients that reported on patients with age by 65 years, and they got the data from the MEDLINE and Embase databases. Trials recruiting from the United States were considered eligible for analysis by race and ethnicity. So, in terms of race and ethnic enrollment, they found that black patients were significantly underrepresented in the industry's funded trials. Notably, no significant disparity was observed in the US government-funded trials, but Hispanics were also significantly underrepresented in industry-funded clinical trials. However, no significant disparity was seen in terms of older adults overall and by funding sources. Remarkably, Black patients' representation in industry-funded prostate cancer trials has actually decreased over the last three decades. Dr. Neeraj Agarwal: That's concerning. So, what is your key takeaway from this trial, Jeanny? Dr. Jeanny Aragon-Ching: The key message here is that Black and Hispanic men with prostate cancer are significantly less likely to be included in industry-sponsored clinical trials. A bigger concern is that black patients' representation actually continues to decline over time. So these results warrant a really more proactive role by regulatory bodies to ensure that a proportional representation of minorities in the industry trials, which in turn will make these results more applicable to a wider entire population of men with prostate cancer. Dr. Neeraj Agarwal: Thanks, Jeanny. Let's move on to renal cell carcinoma. I saw some innovative research correlating the efficacy of immune checkpoint inhibitors with the time of the day these checkpoint inhibitors were administered. So, interestingly, there were two studies from two different groups of investigators showing very similar results. Please tell us about this innovative research correlating outcomes with immune checkpoint inhibitors with the time of the day these medicines or these drugs were infused into the patients. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. I think they're very exciting and interesting. So there's actually two abstracts, so Abstract 681 and 678, which we, of course, can discuss separately. So, let's probably start first with Abstract 678. Neeraj, do you want to explain to us further about this abstract? Dr. Neeraj Agarwal: Yes. When our center participated in that abstract, which was led by Dr. Nazli Dizman from Yale University, Dr. Dizman and colleagues examined the relationship between the time of the administration of immune checkpoint inhibitors, or ICIs, as we call them, during the time of the day, and outcomes in patients with metastatic renal cell carcinoma. So, I'd like to point out that previously Dr. Qian and colleagues reported an association between the time of day of immunotherapy infusion and survival outcomes in patients with metastatic melanoma. In this study, Dr. Dizman and colleagues, which included our center also, patients with metastatic RCC who received nivolumab with or without ipilimumab– so these patients all received either nivolumab alone or without ipilimumab. And patients who received less than 25% of infusion after 4:30 pm. were assigned to the early-time of infusion group. So, if they have received less than 25% infusion of these immunotherapies after 04:30 pm in the evening, they belong to the early infusion group, and the rest were assigned to the late infusion group. In the univariate analysis, numerically higher objective responses and time to treatment failure were observed in the early infusion group compared to the late infusion group. So, differences were 33% versus 25% in objective responses in early versus late infusion group. If you look at time to treatment failure, 8.3 months versus 4.4 months in early versus late infusion group. In the multivariate models, which took into account the clinical characteristics such as age, gender, line of treatment, IMDC risk category, histological subtypes, there was a trend towards improved outcomes in those who received these infusions with ICIs early in the day. So, Dr. Dizman concluded that larger randomized and controlled investigations are warranted to examine the impact of this chronal modulation, if you will, on the efficacy of immune checkpoint inhibitors in metastatic RCC sets. Dr. Jeanny Aragon-Ching: Yeah, this is very interesting data, Neeraj. And that actually resonates closely with this other abstract by Fernandez Manias and colleagues in Abstract 681. So, in this abstract, the primary outcome was overall survival, but they did look at other secondary endpoints like time on treatment, time to the next treatment, and overall response rates. Now, because of the small number of events, the authors actually focused on just patients who received second-line immune checkpoint inhibitors. And what they did was they looked at patients who received overall more than 20% of their infusions after 04:30 pm, and they found that those who did receive actually fewer infusions had a significantly shorter time on treatment and had a worse overall survival. And similar results were seen when they looked at those who got more than 50% of their dose of checkpoint inhibitors that were administered after 04:30 pm, so interestingly enough, there was a 16% increase in the risk of death for each 10% increment of checkpoint infusion after 04:30 pm. So the key message here is that administration of checkpoint inhibitors after 04:30 pm is associated, unfortunately, with inferior outcomes. Now, these results should, of course, be further considered in the organization overall of the outpatient clinic as it can impact patient survival and outcomes. Dr. Neeraj Agarwal: Very interesting. So similar results from two independent groups of investigators from two different continents obviously made this research area very appealing and pertinent. Ideally, I think these results should be validated prospectively, but that will take time. But investigators who have already lagged multiple phase III trials should explore validating these results in the last phase 3 trials which have already been reported and where the data on the timing of infusion is available. Once validated, I think these results may profoundly influence how we organize, as you said, Jeanny, the outpatient scheduling of these checkpoint therapy infusions compared to those who are not checkpoint inhibitors. I think this is going to have very interesting data overall, no doubt. Before moving onto bladder cancer, I would like to discuss an important abstract related to testicular cancer patients titled “Longitudinal Evaluation of Plasma MicroRNA-371 to Detect Minimal Residual Disease and Early Relapse of Germ Cell Tumors.” Could you please tell us more about this abstract? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this is a very interesting up-and-coming Abstract, it's number 407, which will be presented by Dr. Lucia Nappi and colleagues. In this study, clinical patients with stage I germ cell tumor with available plasma samples after they underwent radical orchiectomy were all included. So, they looked at sensitivity, specificity, negative, positive predictive values, an area under the curve in predicting tumor recurrence, and they evaluated the microRNA-371, I'll just call it and truncate it as miR-371, and compared the same operating characteristics of current gold standard diagnostic tests. Relapse-free survival was correlated to post-orchiectomy miR-371 status, which could be either positive or negative. So, at a median follow-up of 41 months, 101 patients with clinical stage one germ cell tumor were included. About 35% of them experienced a disease relapse during that time of follow-up. Now, what they found was miR-371 was positive in about 63% of the relapsed patients, and the miR-371 positivity preceded clinically evident disease by a median of about three months. The specificity and positive predictive values were 100%, sensitivity was like 63%, and negative predictive value was 83.5%, so very high. No false positive results were seen. And, the authors reported that the recurrence-free survival of the patients who had positive post-orchiectomy miR-371 was significantly shorter compared to those patients who had a negative biomarker for the miR-371. So, they concluded that the miR-371 sensitivity correlated with the tumor burden, time between tumor relapse, the microRNA testing, and histology. It was notably a little bit more sensitive in non-seminomas compared to those who had seminoma. Dr. Neeraj Agarwal: Interesting findings, indeed. So, Jeanny, what is the take-home message from this abstract? Dr. Jeanny Aragon-Ching: Yeah, so I think the key takeaway is that microRNA-371 seems to be a good test, like a biomarker for predicting disease relapse in patients with early-stage germ cell tumor. So, additionally, its high specificity and positive predictive value in predicting relapse could really be used and utilized to guide adjuvant therapy, selections, and decisions after orchiectomy. Further validation in other studies, such as swab 1823, are currently ongoing or planned to validate its clinical utility. So Neeraj, moving on to bladder cancer, the last abstract I'd like to mention before we wrap up the podcast is Abstract 563, titled “Utility of ctDNA in Predicting Outcome and Pathological Complete Response in Patients with Bladder Cancer as a Guide for Selective Bladder Preservation Strategies.” Neeraj, can you tell us more about this abstract? Dr. Neeraj Agarwal: Sure. So, this study was led by Dr. Lars Dyrskjøt. He and colleagues evaluated the prognostic value of circulating tumor DNA, or ctDNA, in predicting recurrence in a cohort of 68 patients with muscle-invasive bladder cancer who received new adjuvant chemotherapy prior to cystectomy. So ctDNA was analyzed two times at baseline before new adjuvant chemotherapy and then before surgery or before cystectomy. So, patients had ctDNA assessed before neoadjuvant chemotherapy and then before cystectomy after completion of new adjuvant chemotherapy. At baseline, of the 64 patients, around 60% were ctDNA negative, and 40% were positive for ctDNA. So of those patients who were ctDNA negative, 84% achieved pathologic complete response, while in those who tested ctDNA positive, only 35% achieved their pathologic complete response after surgery. Prior to surgery, 84% of patients were ctDNA negative, and 81% achieved pathologic complete response. While none of the ctDNA-positive patients who were positive before surgery and after neoadjuvant chemotherapy, none of them achieved pathologic complete response, which translates into a positive predictive value of 100% and a negative predictive value of 81% for this test. So based on both ctDNA time points, the probability of ctDNA negative patients to achieve a pathologic complete response was significantly higher than ctDNA positive patients. At a median follow-up of 59 months, ctDNA-positive patients without pathologic complete response demonstrated significantly lower recurrence-free survival and overall survival compared to those who were ctDNA negative. So, I want to repeat that, at a longer follow-up, which Dr. Dyrskjøt will be presenting, ctDNA positive patients without pathologic complete response had significantly lower recurrence-free survival and overall survival compared to ctDNA negative patients. Furthermore, ctDNA status at baseline, which is before neoadjuvant chemotherapy and before cystectomy, was a better predictor of recurrence-free survival compared to pathologic complete response, which is a remarkable finding here, although it's a smaller data set. Dr. Jeanny Aragon-Ching: Agree completely, Neeraj. So, I think the importance here, too, is upon prospective validation in larger data sets, we will find that a negative ctDNA test would help in identifying patients who can benefit more from bladder-sparing strategies. Neeraj, any final thoughts before we wrap up the podcast today? Dr. Neeraj Agarwal: Before I share my final thoughts, Jeanny, I would like to thank you for joining us and sharing your insights. I always find them very valuable. So, thank you so much for taking the time. I would like to wrap up the podcast by saying we are seeing an explosion in the development of novel therapeutic approaches for our patients with genitourinary cancers. At the 2023 ASCO GU meeting, we will have multiple studies with practice-impacting data presented by investigators from around the world. I urge our listeners to come and join us in the meeting not only to celebrate these successes but also to help disseminate these cutting-edge data to practitioners and maximize the benefit for our patients across the globe. I would like to thank our listeners for joining us today. You will find links to the abstracts which we discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Neeraj Agarwal @neerajaimms Dr. Jeanny Aragon-Ching Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, AstraZeneca/MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb , Astellas/Seattle Genetics Travel, Accommodations, Expenses: Dendreon, Algeta/Bayer, Bristol Myers Squibb, EMD Serono, Astellas Pharma
Amber Barnato is an expert in simulation studies. A health services researcher and palliative care physician, Amber lauds the ability of simulation studies to isolate one variable in a study. For example, we spend the first half talking about a RCT simulation study of clinician verbal and non-verbal communication with a seriously ill patient with cancer. In one room the physician under study interacts with a white patient-actor, and in another room interacts with a Black patient-actor. They found no differences in verbal communication, but clear differences in non-verbal rapport building communication: physicians stood farther away, crossed their arms, didn't touch the Black patient as frequently. Amber tells the moving story of how these findings led a clinical colleague, her chief, to question and change his behavior. Of note, we talked about implicit bias in depth in this podcast with Kimberely Courseen. As we've written about on GeriPal when we were a blog (a decade ago!) these simulation studies can be used to study language, such as patient or surrogate choices when we use the terms “allow natural death” vs “do-not-resuscitate.” This change in framing is a nudge, more evidence that the choices we make to use one phrase or another, or the order in which we present options, are all nudges that influence patient choice - listen to our podcast on the ethics of nudging with Jenny Blumenthal-Barby and Scott Halpern for more. Additional links to simulation studies: https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.201411-495OC https://journals.lww.com/ccmjournal/Abstract/2011/07000/A_randomized_trial_of_the_effect_of_patient_race.9.aspx https://www.liebertpub.com/doi/full/10.1089/jpm.2015.0089 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687021/ https://journals.sagepub.com/doi/pdf/10.1177/0272989X14522099 Theoretical underpinnings: https://home.csulb.edu/~cwallis/382/readings/482/nisbett%20saying%20more.pdf
PETBRICK "LYSERGIC AURA"LADY NEPTUNE "OH"BLACK MAGNET "LAST CURSE"DROWSE "TELEPRESENCE"HAVE A NICE LIFE "EARTHMOVER"ALTAR OF GORE "INFINITE VISIONS OF VIOLENCE"MORBID SPHERE "BLACK LIQUID"NECROMANTIC WORSHIP "THE CALLING"NECROMANTIC WORSHIP "FACELESS GODS"LEVIATHAN "UNFAILING FALL INTO NAUGHT"CHRISTINA VANTZOU "SURREAL PRESENCE"
Western culture relies extensively on written text to communicate. But the majority of people across the world rely far less on reading than they do on speech, body language, story, images, and their other senses. Charles Madinger joins the podcast this week to explore the concept of orality—the multifaceted way in which people were created to communicate. Though well-meaning pastors and missionaries may rely on three-point sermons and Bible translation projects, these efforts often miss the variety of ways that the active, living Word of God engages people's bodies and minds, in communities. Charles also examines Jesus' parables and the many ways God interacts with his people throughout Scripture, how McDonald's might do a better job communicating than most pastors, and whether Gen Z is escaping the low orality-reliance of Western culture. Dr. Charles Madinger is the Founder and Director of the Institutes for Orality Strategies, a collective of organizations committed to evangelizing to oral communicators. In addition to his scholarly publications in the field of orality, he has worked in global ministry for thirty years. He also serves the 4.2.20 Foundation as the Vice President of the Center for Oral Scriptures. Show notes: 0:00 Inner and outer speech 5:00 How do we best communicate? 7:39 Memory and multi-sensory communication 13:55 High versus low orality-reliance 16:40 Abstract versus concrete 23:00 Communication in the Bible 27:52 Carrying the Word of God in our bodies 30:29 The Western mind 36:03 The Gutenberg parenthesis 39:00 Teaching like Jesus taught Show notes by Micah Long
In this story, our adventurer discovers an ice cream shop with a strange feature. Welcome to Midnight Slumber! We have a fun short story for you. Sit back, relax, enjoy this short story, and thanks for listening! Written and Narrated by Zack Miller. Follow us on Twitter @The_MNS_Podcast, Instagram @midnight_slumber_podcast, our YouTube Channel - Midnight Slumber, and on Facebook – Midnight Slumber.